DS
PHIO icon

DRW Securities’s Phio Pharmaceuticals PHIO Stock Holding History

DRW Securities’s Portfolio PHIO Stock Details PHIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-22,636
Closed -$23.8K – 1624
2025
Q4 		$23.8K Buy
+22,636
New +$36.2K ﹤0.01% 1158
2018
Q3 		– Sell
-3
Closed -$37K – 86
2018
Q2 		$37K Hold
3
– – ﹤0.01% 97
2018
Q1 		$61K Buy
+3
New +$69K ﹤0.01% 158

Other funds holding PHIO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SRL
Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

DRW Securities's PHIO Position: Q1 2026 in Review

DRW Securities sold out of Phio Pharmaceuticals (PHIO) in Q1 2026, closing a stake of 22,636 shares — an estimated $23.8K sold.

DRW Securities first reported a position in PHIO in Q1 2018 and held it in 3 quarters. The position peaked at $61K in Q1 2018. 24 funds tracked by Wall St. Rank hold PHIO as of Q1 2026.

  • DRW Securities reported no remaining Phio Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • DRW Securities sold 22,636 Phio Pharmaceuticals shares in Q1 2026, an estimated $23.8K.
  • DRW Securities first reported a position in Phio Pharmaceuticals in Q1 2018 and held it in 3 quarters.
  • DRW Securities's Phio Pharmaceuticals position peaked at $61K in Q1 2018.
  • 24 funds tracked by Wall St. Rank held Phio Pharmaceuticals as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.